Sage Therapeutics, Inc. SAGE reported a loss of $1.56 per share for the fourth quarter of 2024, wider than the Zacks ...

Biogen expects 2025 non-GAAP EPS of $15.25-$16.25 and a mid-single-digit decline in total revenue, primarily due to MS franchise pressures, including potential biosimilar and generic entries. Growth ...

Failed to fetch dynamically imported module: https://finance.yahoo.com/assets/_app/immutable/nodes/2.3cY8rBmp.js ...

Biogen Inc. CEO Christopher Viehbacher gave investors an overview of what type of deals the company is looking for Wednesday ...

The funding agreement comes as Biogen revealed a modest Q4 sales beat, which analysts expect will be “overshadowed” by the ...

H.C. Wainwright analyst Douglas Tsao revised the price target for Sage Therapeutics (NASDAQ:SAGE) to $12.00 from the previous $14.00 while maintaining a Neutral rating on the company's shares. Tsao's ...

The 12-month price targets, analyzed by analysts, offer insights with an average target of $8.86, a high estimate of $14.00, ...

Sage Therapeutics, Inc. (Nasdaq: SAGE), today reported business highlights and financial results for the fourth quarter and full year ended December 31, 2024. "We ...

Sage Therapeutics Inc. pushed off questions about potential mergers or acquisitions during its first earnings call since ...

Based on the Company’s current operating plan, Sage anticipates that its existing cash, cash equivalents, and marketable ...

But we expect Breville will need to continue to invest to maintain its brand equity and differentiate its products from lower-end competitors amid global expansion. We forecast the firm will maintain ...

President Jeff Dobyns unpacks the strategic power of mentorship, what makes an "ideal team player," and how the firm's 89 ...